Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Restasis (Cyclosporine) Ophthalmic Emulsion Prescribers: Ophthalmologists (US)

Analysis of: Genentech to cease supplying bevacizumab to compounding pharmacies (www.osnsupersite.com)
Genentech, Inc.  is suspending sales of Avastin (bevacizumab) to compounding pharmacies in the United STates, in an effort to curb its non approved use for wet macular degenration. Recently, ophthalmologists have begun using the antiangiogenic cancer drug off-label to treat retinal neovascularization...
Analysis of: Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501 (www.pipelinereview.com)
Alacrity Biosciences has completed a Phase 2 clinical trial of ALTY-1501, an eye drop for the treatment of dry eye. Dry eye (or keratoconjunctivitis sicca (KCS) affects more than 10% of the US population and its incidence is increasing as baby boomers become senior citizens. Although the small...
Analysis of: Maker Seeks to Restrict Cancer Drug Used on Eye (www.nytimes.com)
       Genentech has had first year revenues of $800 million from its drug Lucentis, which is used intravitreaaly to treat macular degeneration on label and some other conditions off label.   Although this amount of sales places Lucentis well within the blockbuster...
Analysis of: Inspire Completes Enrollment in Phase 3 Cystic Fibrosis Trial (www.pipelinereview.com)
Inspire Pharmaceuticals' founding concept is based upon P2Y2 receptor agonist technology, now approaching fruition with groundbreaking cystic fibrosis (CF) clinicals.  Well tolerated three times daily nebulizer therapy with denufosol for young CF patients promises improved pulmonary function,...
Analysis of: IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth (www.pnas.org)
Omega-3 supplementation could be a useful strategy for protecting against retinopathy of prematurity (ROP), say Swedish investigators. In the study, mice with retinopathy were fed food enriched with either omega-3 or omega-6. Mice that ate omega-3 initially lost fewer retinal blood vessels than mice...
Analysis of: Blood Pressure, Arterial Stiffness, & Open Angle Glaucoma: The Rotterdam Study (archopht.ama-assn.org)
Patients with high arterial pulse pressure may be at increased risk for high-tension open angle glaucoma, a Dutch study concludes. Researchers analyzed data from 5,317 individuals, 215 of who had definite or probable open-angle glaucoma and 5,102 of whom were disease free.The analysis found that high-tension...
Analysis of: Ophthalmic business: Alcon exceeds 70% stake in WaveLight (www.osnsupersite.com)
Alcon holds more than 70% of Wavelights shares and its takeover of Wavelight has been approved by the German authorities. WHile wavelight produces some interesting intraocular lenses, it is clear that Alcons interest in Wavelight lies in its realiable and fast excimer laser system that can be used for...
Analysis of: Targeting amyloid- b in Glaucoma (www.pnas.org)
New research indicating the presence of amyloid-beta protein in dying retinal cells  suggests a new direction in glaucoma research. Amyloid-beta is a protein found in Alzheimer's plaques. Using a rat model of glaucoma, the researchers found that the dying retinal cells showed accumulation of amyloid-beta....
Mark Packer, MD, Clinical Associate Professor of Ophthalmology
Mark Packer, MD, Clinical Associate Professor of Ophthalmology
OREGON HEALTH & SCIENCE UNIVERSITY - CC
August 30, 2007
Eyeonics Going Public
Analysis of: Eyeonics Files For IPO (www.socaltech.com)
Rather than getting gobbled up by one of the big three players in Ophthalmology (B & L, Alcon and AMO), eyeonics is looking to go it alone into the public arena.  The crystalens remains the only approved accommodative intraocular lens, but faces strong competition from the multifocals. ...
Analysis of: Tears in the Retinal Pigment Epithelium: A Complication Associated with the New Macular Degeneration Treatments (pt.wkhealth.com)
Tears of the retinal pigment epithelium (RPE) may develop during the course of anti-VEGF therapy for age-related macular degeneration (AMD) related pigment epithelial detachment (PED), according to a study published in the June issue of Retina.  A total of 33 cases of RPE tear after treatment with...

Previous Page : 1 2 3 4 5 6 7 Next11 to 20 of 68

Analytics


Generated at 2009-01-09T13:00:20.343